

1

1 **Exponential Strand-Displacement Amplification for Detection of microRNAs**

2

3 **Chao Shi^{a,b}, Qi Liu^a, Cuiping Ma^{a,*}, Wenwan Zhong^{b,*}**

4

5^a*State Key Laboratory Base of Eco-chemical Engineering□College of Chemistry and*

6*Molecular Engineering□Qingdao University of Science and Technology□Qingdao*

7*7266042□P. R.China.*

8^b*Department of Chemistry, University of California, Riverside, California 92521-*

9*90403, United States*

10

11

12

13

14***Corresponding authors.**

15**Dr. Wenwan Zhong; Tel.: +1-951-827-3532; Fax: +1-951-827-4713.**

16**E-mail: wenwan.zhong@ucr.edu**

17**Dr. Cuiping Ma; Tel. (Fax.): +86-84022680. E-mail: mcp169@163.com**

18

19

20

21

22

23

24

25ABSTRACT

26 MicroRNAs are promising targets for disease diagnosis. However, miRNA
27detection requires rapid, sensitive and selective detection to be effective as a
28diagnostic tool~~To take full advantage of the great potential of miRNAs as biomarkers~~
29~~for disease diagnosis, simple, rapid and sensitive methods for miRNA detection~~
30~~should be developed~~. Herein, a miRNA-initiated exponential strand-displacement
31amplification (SDA) assay was reported. ~~With the Klenow fragment, and the nicking~~
32~~enzyme *Nt.AlwI*, and two primers, the miRNA target can trigger triggered two cycles~~
33~~of nicking, polymerization, and displacement reactions, using two strategically~~
34~~designed primers~~. These reaction cycles amplified the target miRNA exponentially
35and generated dsDNAs detectable with SYBR Green I in real-time PCR. As low as
3616 zmol of the target miRNA was detected by this one-pot assay within 90 minutes,
37and the dynamic range spanned over 9 orders of magnitude. ~~Negligible impact from~~
38~~the complex biological matrix was observed on the amplification reaction, indicating~~
39~~high potential of our assay to detect circulating miRNAs in biofluids~~the assay's ability
40to directly detect miRNA levels in biofluids.

41

42

43

44

45

46**Keywords:** microRNAs; Exponential strand-displacement amplification;

47Homogeneous detection; Isothermal amplification□nicking enzyme

48

49 MicroRNAs (miRNAs, ~ 22 nt) regulate gene expression by binding to target
50mRNAs, which can either inhibit translation or induce degradation of target
51transcripts. Such regulatory roles render miRNAs capable of possible capability to
52modulate tumor development, progression and metastasis.¹⁻⁷ Compared to
53proteins, miRNAs have simpler structure and less complex post-synthetic
54processing. These features make miRNAs promising biomarkers for cancer
55screening. Sensitive detection of the expression levels of miRNAs in biological
56samples or clinical specimens is thus of great importance to cancer diagnosis,
57enabling timely disease intervention and enhance the survival rate of patients.⁸

58 The short length of miRNAs and their low abundance in biological samples
59increases the difficulty in miRNA detection.⁹ Conventional methods, including
60northern blotting, real-time PCR, and microarrays, possess limitations like such as
61insufficient sensitivity, tedious sample preparation and analysis, long and tedious
62process, requirement of sophisticated instruments, sophisticated instrumentation, and
63high operation expenses, etc.⁷ In the past decade, many new methods have been
64developed to improve miRNA detection. Among them, isothermal amplification of
65miRNAs using a combination of DNA polymerases and processing enzymes have
66attracted great attention, because of their high detection sensitivity, fast reaction
67speed, and low operational cost.¹²⁻¹⁷ However, oligonucleotides with sophisticated
68designs, like the dumbbell-shaped probe,¹⁴ circular template,¹³ hairpin structures,
69fluorescently labeled strands,¹⁶ etc., are required. Or, nanomaterials are employed to

70 ~~assist with signaling~~ Nanomaterials may also be used to aid signaling.¹⁵ Alternatively,
71 isothermal amplifications originally designed for DNAs, such as the loop-mediated
72 isothermal amplification (LAMP)¹⁸ and the exponential amplification reaction
73 (EXPAR)¹⁹ can be applied to detect miRNAs with strategic modifications to the
74 hybridization probes.

75 Herein, we reported a very simple and ultrasensitive detection method for
76 miRNAs that was established upon the exponential strand-displacement amplification
77 (SDA) originally designed for dsDNAs.²² Common strand-displacement reactions
78 amplify target nucleic acids linearly,²³⁻²⁵ but exponential SDA overcome this limitation
79 by employing four primers. Our present study demonstrated that, for detection of
80 miRNAs, only two primers were needed to achieve to same exponential amplification
81 effect by SDA, comparable exponential amplification to SDA, which rendered sensitive
82 detection of the target miRNA in complex biological matrix. Deliberate selection of
83 the polymerase and the nicking enzyme enabled one-pot, rapid amplification under
84 one mild reaction temperature, offering high potential for point-of-care diagnosis.

85 Scheme 1 illustrates the steps of the miRNA-initiated SDA. Exponential
86 amplification is achieved with two repeated cycles of nicking, polymerization and
87 displacement reactions, each assisted by one primer. Once the target miRNA
88 hybridizes to the 3' end of Primer 1, the Klenow fragment polymerase (exo⁻) extends
89 both Primer 1 and the miRNA, producing a chimeric double-stranded fragment.
90 Followed Next, Nt.AfwI creates a strand break on Primer 1 at the site 4 random
91 nucleotides downstream of the recognition sequence. This break then primes the first

92 amplification cycle of displacement, nicking and polymerization, producing ssDNA
93 T*. T* is complementary to the target miRNA. T* hybridizes with Primer 2 at its 3'
94 end, and both are extended by the Klenow fragment. Primer 2 also includes the
95 recognition sequence of *Nt.AlwI* at its 5' end, so that the second amplification cycle
96 can be triggered. The displaced ssDNA, has the same sequence as that of the target
97 miRNA but with all U nucleotides replaced by T. The two amplification cycles
98 continue to produce T and T*, which hybridize and form dsDNAs easily detectible by
99 SYBR Green I.

100 **The feasibility of our assay was demonstrated by testing the products of each**
101 **reaction cycle by PAGE** (Figure 1). The reaction was initiated by the 22-nt miRNA
102 *Let-7a* (sequence listed in Table 1 with other oligonucleotides used in this study).
103 Lane 1 showed that *Let-7a* migrated slightly faster than the 20-bp band of the DNA
104 ladder (Lane M), but its hybridization product with Primer 1 moved slower (Lane 2).
105 With addition of the Klenow fragment (exo⁻), a chimeric DNA/RNA hybrid of 32 bp
106 was formed (Lane 3), appearing close to the 40-bp band of the ladder. This band was
107 much brighter than that in Lane 2, because successful extension of both the target
108 miRNA and Primer 1 generated dsDNAs that gave out strong signal with SYBR
109 Green I compared to ssDNAs. Once the nicking enzyme, *Nt.AlwI*, was added, the 32-
110 bp fragment was cut, leaving a gap on this extension product (Lane 4). The Klenow
111 fragment then grew a new strand to displace the original extension product T* off. In
112 Lane 4, the lower band that migrated similarly to the 20-bp fragment of the ladder
113 should be the hybridized product of T* and *Let-7a*, because a relatively high

114 concentration of the target miRNA was used for visualization on the gel. At last, we
115 mixed T, Primer 1, Klenow, *Nt.AlwI*, and Primer 2 to trigger both amplification
116 cycles. Although ~~with~~ having a ten-fold lower target concentration, the exponential
117 amplification generated more of the 32-bp products than with the single cycle in Lane
1184.

119 The Klenow fragment has no 3' → 5' exonuclease activity, and cannot remove
120 non-templated 3' addition. It is possible that 1-3 nucleotides would be randomly
121 added to the end of the extension product from Primer 1,²⁸ and participate in
122 hybridization with Primer 2. This could be problematic because the amplification
123 cycle would be stopped if fully complementary binding with Primer 2 was not
124 formed. Since the random overhangs would hybridize with the 4 nucleotides between
125 the cleavage site and the recognition sequence for *Nt.AlwI*, we optimized their
126 sequences to obtain the best amplification effect. Based on the study conducted by
127 Garcia *et al.*,²⁸ addition of dATP was 5 times faster than other dNTPs. Indeed, a T
128 base upstream to the cleavage site in both primers increased the amplification rate
129 (Supporting Information Figure S1). ~~Though~~ However, increasing the number of T
130 base did not further speed up the reaction improve the rate further. Thus, 5'-CTCT-3'
131 and 5'-GTCT-3' were chosen to flank the recognition region and the cleave site on
132 Primer 1 and Primer 2, respectively, in the following studies. Additionally, the
133 concentrations of both enzymes used in our assay were optimized (Supporting
134 Information Figure S2).

135 With the appropriate primer design and optimized enzyme concentrations, we

136tested the sensitivity and specificity of the assay. Both enzymes and the two primers
137were mixed with *Let-7a*, dNTPs, and SYBR Green I in 1×NEB buffer 2, yielding a
138total reaction volume of 10 μL. The reaction temperature was set at 37 °C in the
139CFX96™ Real-Time PCR detection system (Bio-Rad); and every reaction cycle
140lasted one minute, which included a 30-s scan to record the increase of fluorescence
141and 30 s interval time. Within 90 minutes, 1.0 pmol to 0.1 zmol *Let-7a* were detected
142(Figure 2). The C_q values were linearly related to the negative logarithmic (lg) value
143of the miRNA amount ($R^2=0.9865$). The limit of detection was calculated to be 16
144zmol using the 3σ method.

145 To evaluate the specificity of our design, 0.1 pmol of selected members of the *Let-*
1467 miRNA family (*Let-7a*, 7b, 7c, 7e and 7i; sequences in Table 1) at the amount of 0.1
147pmol were detected by the primer pair designed for using the *Let-7a* primer pair.

148Figure 3 showed that, the C_t value for *Let-7a* was significantly smaller than that for
149*Let-7e*, -7b, and -7i, which were listed here in the order of increasing C_t values. The
150sequence of *Let-7e* differs from *Let-7a* with only one U (in 7a) → G (in 7e) mutation,
151but the mutation locates close to the 3' end of Primer 2. Extension of Primer 2 was
152thus disturbed, leading to low yield in the second amplification cycle. This also
153proved that the overall amplification effect should rely on successful progression of
154both cycles. However, it is difficult to distinguish between *Let-7a* and -7c, which also
155differ in only one nucleotide. The mutated base located in the middle of the
156hybridization region between primer 1 and *Let-7a*, which had low influence to the
157extension of Primer 1.

158 It has been known that miRNAs can be released into the circulation system;²⁹⁻
159³² and accumulating evidences also show that circulating miRNAs exhibit varied
160patterns between cancer patients and healthy controls.³³⁻³⁵ Thus, it will be highly
161useful for cancer diagnosis if our assay can be used to detect the levels of circulating
162miRNAs in biofluids like serum. To demonstrate this, we spiked 0.1 fmol to 0.1 pmol
163*Let-7a* into ~~the~~ commercial human serum (Lonza Biowhittaker human serum from
164Fisher Scientific), in which ~~the~~ endogenous *Let-7a* was not detectable using the
165Taqman® RT-PCR kit ~~for miRNAs~~ (Life Technologies, Inc.). The serum was diluted
1662 times in the 10- μ L reaction mixture. Using the same reaction conditions as
167mentioned above, the Cq values increased linearly with the negative logarithmic value
168of the amount of target miRNA, and the regression equation was found to be: Cq =
169-130.1125 + 10.35186 (-lgA_{*Let-7a*}) (A_{*Let-7a*} was the concentration of *Let-7a*, R²=0.9681)
170(see Figure S3 in the Supporting Information). This relationship was almost the same
171as that for the standard curve obtained at the same time (Cq = -130.718 + 10.426 (-
172lgA_{*Let-7a*}), R²=0.9901), proving that the reaction was not affected by the complex
173components in serum. ~~The method posses good ability of anti-jamming in biofluids~~
174~~like serum. Owing to the potential for the use of serum miRNAs as biomarkers of~~
175~~disease and as targets of therapeutics, so our method is promising as a non-invasive,~~
176~~highly sensitive, and accurate diagnosis for cancer.~~

177 In summary, ~~the a~~ one-pot, miRNA-assisted exponential SDA for quick and easy
178detection of miRNAs in biological samples has been developed. It yielded low limit
179of detection, has a large detection range, and provides good selectivity. Our method

180only requires two non-labeled primers with very simple design, yields exponential
181amplification, and performs at a mild temperature of 37 °C. In contrast to previously
182detecting microRNA methods, our method does not require any modified DNA, and can be ~~real-~~
183~~timely~~-detected by in real time using SYBR Green I as the fluorescent dye. This greatly reduced
184the detection cost. Moreover, the method posses good ability of anti-jamming iis resistant to
185matrix interference, even in complex biofluids like such as serum. This simple and cost-effective
186method has the potential to become an attractive tool for quantitative analysis of miRNAs
187(biomarkers) in tissues or cells and gives valuable information for the fields of basic and clinic
188research and diagnostics.

189ACKNOWLEDGMENT

190 The work was supported by the National Science Foundation CAREER Grant #
191CHE-1057113 to Dr. W. Zhong; the National Natural Science Foundation of China
192(31170758, 21375071, 21307064), the Science and Technology Development Project
193of Shandong Province (2012GSF12001), and the Science and Technology
194Development Project of Qingdao (12-1-3-62-nsh) to Dr. C. Shi and Dr. C. Ma.


195 **Table 1. Sequences of DNA and RNA in experiment.**

miRNA	Sequence (5' to 3') ^a
<i>Let-7a</i>	UGAGGUAGUAGGUUGUAUAGUU
<i>Let-7b</i>	UGAGGUAGUAGGUUGUG <u>UG</u> GUU
<i>Let-7c</i>	UGAGGUAGUAGGUUGU <u>A</u> UGGUU
<i>Let-7e</i>	UGAGGUAG <u>G</u> AGGUUGUAUAGUU
<i>Let-7i</i>	UGAGGUAGUAG <u>UUUG</u> <u>GCU</u> GUU
Primer 1	<u>CGGATCCTCT</u> !AACTATACAACC
Primer 2	<u>CGGATCCTCT</u> !TGAGGTAGTAGG
<p>^a The portions underlined in primers indicate the recognition site of the nicking enzyme <i>Nt.AlvI</i> and the arrowheads (!) show the cutting site. The italic portions in Primer1 and 2 are the complementary sequence T and T*, respectively. The underlined and italic bases in the <i>Let</i> miRNAs are the bases different than those in <i>Let-7a</i>.</p>	


196

197 **Scheme 1.** Schematic illustration of exponential SDA initiated by miRNA *Let-7a*. The
 198 sequences of the target and primers are listed in Table 1.
 199


200



201**Figure 1.** The result of analyzing the amplification products by PAGE (17.5%
 202polyacrylamide). **M:** 20-bp DNA ladder; **1:** 1.0×10^{-5} M Target; The product of
 203amplification reaction in **2:** 10 μ L mixture containing 1.0×10^{-6} M Primer 1 and $1.0 \times$
 204 10^{-6} M the target, 0.3 μ L 2.5 mM dNTPs, 1 \times NEB buffer 2; **3:** the mixture in Lane 2 +
 2050.1 μ L Klenow fragment (exo⁻); **4:** the mixture in Lane 3 + 0.6 μ L *Nt.AlwI*; **5:** the
 206mixture in Lane 4 but with a ten-fold lower target concentration + 1.0×10^{-6} M Primer
 2072.



214**Figure 3.** Real-time fluorescence curves for the exponential SDA amplification were
215triggered by 1.0×10^{-13} mol *Let-7a*, *Let-7b*, *Let-7c*, *Let-7e* and *Let-7i*, respectively. The
216other experimental conditions are the same as those for Figure 2.



217

218

219

220

221

222

223

224

225

226

227

228

229

230

231**Supporting Information**

232 This material is available free of charge via the Internet at <http://pubs.acs.org>.

233REFERENCES

- 234(1) Chowdhury, D., Choi, Y.E. & Brault, M.E. *Nat. Rev. Mol. Cell Biol.* 2013, **14**, 181-189.
- 235(2) Wahlestedt, C. *Nat. Rev. Drug Discovery* 2013, **12**, 433-440.
- 236(3) Hauptman, N. & Glavac, D. *Int. J. Mol. Sci.* 2013, **14**, 4655-4669.
- 237(4) Kim, T. & Reitmair, A. *Int. J. Mol. Sci.* 2013, **14**, 4934-4968.
- 238(5) Nicoloso, M.S., Spizzo, R., Shimizu, M., Rossi, S. & Calin, G.A. *Nat. Rev. Cancer* 2009, **9**, 293-239302.
- 240(6) Volinia, S., *et al.* *Genome Res.* 2010, **20**, 589-599.
- 241(7) Ventura, A. & Jacks, T. *Cell* 2009, **136**, 586-591.
- 242(8) Wark, A.W., Lee, H.J. & Corn, R.M. *Angew Chem Int Ed* 2008, **47**, 644-652.
- 243(9) Valoczi, A., *et al.* *Nucleic Acids Res* 2004, **32**, e175.
- 244(10) Lagos-Quintana, M., Rauhut, R., Lendeckel, W. & Tuschl, T. *Science* 2001, **294**, 853-858.
- 245(11) Lee, I., *et al.* *Nucleic Acids Res* 2008, **36**, e27.
- 246(12) Duan, R., *et al.* *J. Am. Chem. Soc.* 2013, **135**, 4604-4607.
- 247(13) Yao, B., *et al.* *Rna* 2009, **15**, 1787-1794.
- 248(14) Bi, S., Cui, Y. & Li, L. *Anal. Chim. Acta* 2013, **760**, 69-74.
- 249(15) Dong, H., *et al.* *Anal. Chem.* 2012, **84**, 4587-4593 (2012).
- 250(16) Tian, T., *et al.* *Chem. Commun.* 2013, **49**, 75-77 (2013).
- 251(17) Wang, G.-l. & Zhang, C.-y. *Anal. Chem.* 2012, **84**, 7037-7042.
- 252(18) Kim, J. & Easley, C.J. *Bioanalysis* 2011, **3**, 227-239.
- 253(19) Van Ness, J., Van Ness, L.K. & Galas, D.J. *Proc. Natl. Acad. Sci. USA* 2003, **100**, 4504-4509.
- 254(20) Jia, H., Li, Z., Liu, C. & Cheng, Y. *Angew. Chem. Intl. Ed.* 2010, **49**, 5498-5501.
- 255(21) Li, C.P., Li, Z.P., Jia, H.X. & Yan, J.L. *Chem. Commun.* 2011, **47**, 2595-2597.
- 256(22) WALKER, G.T., LITTLE, M.C., NADEAU, J.G. & SHANK, D.D. *Proc. Natl. Acad. Sci. USA* 2571992, **89**, 392-396.
- 258(23) Ma, C., Wang, W., Yang, Q., Shi, C. & Cao, L. *Biosens Bioelectron* 2011, **26**, 3309-3312.
- 259(24) Ma, C., Zhao, C., Ge, Y. & Shi, C. *Clin. Chem* 2012, **58**, 384-390.
- 260(25) Shi, C., Zhao, C., Guo, Q. & Ma, C. *Chem Commun* 2011, **47**, 2895-2897.
- 261(26) Walker, G.T., *et al.* *Nucleic Acids Res.* 1992, **20**, 1691-1696.
- 262(27) Little, M.C., *et al.* *Clin. Chem.* 1999, **45**, 777-784.
- 263(28) Garcí a, P.B., Robledo, N.L. & Islas, Ä.L. *Biochemistry* 2004, **43**, 16515-16524.
- 264(29) Creemers, E.E., Tijssen, A.J. & Pinto, Y.M. *Circulation Res.* 2012, **110**, 483-495.
- 265(30) Lagana, A., *et al.* *RNA* 2013, **4**, 120.
- 266(31) Olivieri, F., Rippo, M.R., Procopio, A.D. & Fazioli, F. *Frontiers in Non-Coding RNA* 2013, **4**, 267121.
- 268(32) Rykova, E.Y., Laktionov, P.P. & Vlassov, V.V. *Nucleic Acids Mol. Biol.* 2010, **25**, 93-128 (2010).
- 269(33) Williams, Z., *et al.* *Proc. Natl. Acad. Sci. USA* 2013, **110**, 4255-4260.
- 270(34) Mitchell, P.S., *et al.* *Proc. Natl. Acad. Sci. USA* 2008, **105**, 10513-10518.
- 271(35) Russo, F., *et al.* *PLoS One* 2012, **7**, e47786.


272

273

274

275

276TOC Figure
277



278